ストックスクリーナーアプリを入手
4.90
1.01%
-0.05
アフターアワーズ：
4.95
0.05
+1.02%
前日終値:
$4.95
開ける：
$4.81
24時間の取引高:
8,796
Relative Volume:
0.83
時価総額：
$68.20M
収益：
$57.94M
当期純損益:
$-2.34M
株価収益率:
-29.41
EPS:
-0.1666
ネットキャッシュフロー:
$3.82M
1週間 パフォーマンス:
-7.55%
1か月 パフォーマンス:
-1.61%
6か月 パフォーマンス:
-15.52%
1年 パフォーマンス:
-23.32%
1日の値動き範囲:
$4.8001
$4.955
1週間の範囲:
$4.8001
$5.31
52週間の値動き範囲:
$4.59
$8.3099
Champions Oncology Inc Stock (CSBR) Company Profile
名前
Champions Oncology Inc
セクター
電話
410-369-0365
住所
855 N. WOLFE STREET, BALTIMORE, NJ
Compare CSBR vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CSBR
Champions Oncology Inc
|
4.90 | 68.20M | 57.94M | -2.34M | 3.82M | -0.1666 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-12 | アップグレード | Craig Hallum | Hold → Buy |
| 2019-11-18 | 開始されました | The Benchmark Company | Speculative Buy |
Champions Oncology Inc (CSBR) 最新ニュース
Champions Oncology Inc (2I3.MU) cash flow - au.finance.yahoo.com
Is Champions Oncology (NASDAQ:CSBR) Stock Worth Watching Today? - Kalkine Media
Champions Oncology Q4FY26 Results: Revenue up 12% to $59.4 million - scanx.trade
Full Transcript: Champions Oncology Q4 2026 Earnings Call - Benzinga
Champions Oncology, Inc.Common Stock (Nasdaq:CSBR) Price Chart - The Chronicle-Journal
CSBR Stock Slips Post Q1 Earnings Despite Revenue, Margin Growth - Eastern Progress
Champions Oncology Inc (CSBR) (Q1 2027) Earnings Call Highlights: Data Licensing Surge and ... - Yahoo Finance
Champions Oncology Narrows Q1 Loss to $426,000 - Minichart
CHAMPIONS ONCOLOGY, INC. 1Q 2027: Revenue $15.23M, EPS $(0.03) — 10-Q Summary - TradingView
CSBR 10-Q FilingsChampions Oncology, Inc. SEC 10-Q - stocktitan.net
Champions Oncology Q4 Results: Adjusted EPS beats estimates - scanx.trade
Champions Oncology (CSBR) Q1 2027 Earnings Call Transcript - The Globe and Mail
Champions Oncology, Inc. Q1 2027 Earnings Call Summary - Yahoo Finance
CSBR|Champions Oncology Inc|Price:5.096|Chg%:+0.086 - TradingKey
Champions Oncology posts 8.8% revenue growth an... - Pluang
Champions Oncology Fiscal Q1 2027 Earnings: Margin Expansion Lifts Adjusted EBITDA - TradingKey
Earnings call transcript: Champions Oncology tops Q1 2027 estimates, shares slip - Investing.com Nigeria
Champions Oncology Q1 Results: Adj. EPS up 400% to $0.05 - scanx.trade
Champions Oncology (CSBR) Q1 Fiscal 2027 Earnings Call: Revenue Up 9%, Services Margin Reaches 51% - TradingKey
Champions Oncology Q1 Earnings Call Highlights - Yahoo Finance
Champions Oncology earnings beat by $0.06, revenue topped estimates - Investing.com
Champions Oncology reports Q1 revenue $15.2M, adjusted EBITDA $0.7M and oncology services margin 51% - TradingView
CSBR: Revenue up 8.8% to $15.2M, oncology margin at 51%, adjusted EBITDA $671K, net loss $426K - TradingView
Champions Oncology posts better-than-expected Q1, but shares edge lower on higher costs - Investing.com
Champions Oncology, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2026 - marketscreener.com
CHAMPIONS ONCOLOGY ($CSBR) Releases Q1 2027 Earnings - Quiver Quantitative
Champions Oncology Reports Revenue of $15.2 Million - ACCESS Newswire
Oracle, Adobe, Copart and more set to report earnings Thursday By Investing.com - Investing.com Australia
Oracle, Adobe, Copart and more set to report earnings Thursday - Investing.com
CSBR Q1'26 Earnings: EPS estimate is (0.01) USD - TradingView
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 10, 2026 - Black Hills Pioneer
Champions Oncology Inc. (CSBR) Key Financial Ratios – Valuation, Profitability & More - Value Research
CSBR - Finviz
Champions Oncology Expands Integrated Radiopharmaceutical Development Platform with In-House SPECT/CT Imaging - New Castle News
New imaging follows cancer treatments inside tumors—and links uptake to response - Stock Titan
Champions Oncology adds in-house SPECT/CT imaging to radiopharma platform - scanx.trade
Champions Oncology Inc. (CSBR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Champions Oncology Inc. (CSBR) Peer Comparison – Compare with Others - Value Research
Anixa Biosciences Inc. (ANIX) Peer Comparison – Compare with Others - Value Research
Champions Oncology Inc (NASDAQ: CSBR) Share Price, CSBR Stock News, CSBR Share Price & Updates - kalkine.ca
Champions (CSBR) Range: Finishes 4.86% Up at $5.18 in the Latest Session; Price Setup: the Near-Term Reference Band Stretches From $4.92 to $5.44 in the Available RecordHidden Order - vinanet.vn
North-America Humanized Mouse and Rat Model Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Japan Humanized Mouse and Rat Model Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Rest-Of-Asia-Pacific Humanized Mouse and Rat Model Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Latin-America Humanized Mouse and Rat Model Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Comedian Michael Kosta Headlines Karmanos Comedy Champions on New October Date, Hosted by 101 WRIF's Jade Springart - PR Newswire
Precision Trading with Champions Oncology Inc. (CSBR) Risk Zones - Stock Traders Daily
OSTX Stock Price and Chart — AMEX:OSTX - TradingView
Manulife China Bank Life Champions Early Health Action and Financial Planning at The Art of Longevity - Mindanao Times
Residential Social Vulnerability Associated With Worse Survival Among Black Women With Epithelial Ovarian Cancer - The ASCO Post
China Patient Derived Xenografts/PDX Models Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Champions Oncology Inc (CSBR) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):